Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations

TJ Pugh, SD Weeraratne, TC Archer… - Nature, 2012 - nature.com
Medulloblastomas are the most common malignant brain tumours in children 1 . Identifying
and understanding the genetic events that drive these tumours is critical for the development …

Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort

…, K Kjaerheim, CM Monoranu, TC Archer… - The Lancet …, 2018 - thelancet.com
Background Medulloblastoma is associated with rare hereditary cancer predisposition
syndromes; however, consensus medulloblastoma predisposition genes have not been defined …

SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation

…, J Mieczkowski, Y Drier, SM Gillespie, TC Archer… - Nature …, 2017 - nature.com
SMARCB1 (also known as SNF5, INI1, and BAF47), a core subunit of the SWI/SNF (BAF)
chromatin-remodeling complex 1 , 2 , is inactivated in nearly all pediatric rhabdoid tumors 3 , 4 , …

[PDF][PDF] Proteomics, post-translational modifications, and integrative analyses reveal molecular heterogeneity within medulloblastoma subgroups

TC Archer, T Ehrenberger, F Mundt, MP Gold, K Krug… - Cancer cell, 2018 - cell.com
There is a pressing need to identify therapeutic targets in tumors with low mutation rates
such as the malignant pediatric brain tumor medulloblastoma. To address this challenge, we …

[HTML][HTML] Interaction of Sox1, Sox2, Sox3 and Oct4 during primary neurogenesis

TC Archer, J Jin, ES Casey - Developmental biology, 2011 - Elsevier
Sox1, Sox2 and Sox3, the three members of the SoxB1 subgroup of transcription factors,
have similar sequences, expression patterns and overexpression phenotypes. Thus, it has …

[HTML][HTML] Medulloblastoma: molecular classification-based personal therapeutics

TC Archer, EL Mahoney, SL Pomeroy - Neurotherapeutics, 2017 - Elsevier
Recent advances in cancer genomics have revealed 4 distinct subgroups of medulloblastomas,
each with unique transcription profiles, DNA alterations and clinical outcome. Molecular …

DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets

AR Hanaford, TC Archer, A Price, UD Kahlert… - Clinical Cancer …, 2016 - AACR
Purpose: We used human stem and progenitor cells to develop a genetically accurate novel
model of MYC-driven Group 3 medulloblastoma. We also developed a new informatics …

OTX2 activity at distal regulatory elements shapes the chromatin landscape of group 3 medulloblastoma

G Boulay, ME Awad, N Riggi, TC Archer, S Iyer… - Cancer discovery, 2017 - AACR
Medulloblastoma is the most frequent malignant pediatric brain tumor and is divided into at
least four subgroups known as WNT, SHH, Group 3, and Group 4. Here, we characterized …

COVID-19 Exposure Assessment Tool (CEAT): Exposure quantification based on ventilation, infection prevalence, group characteristics, and behavior

…, NS Trovão, M Isbell, C Goel, BF Heck, TC Archer… - Science …, 2022 - science.org
The coronavirus disease 2019 (COVID-19) Exposure Assessment Tool (CEAT) allows users
to compare respiratory relative risk to severe acute respiratory syndrome coronavirus 2 (…

α5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth

…, D Mathios, M Lechpammer, TC Archer… - Acta …, 2014 - Springer
Neural tumors often express neurotransmitter receptors as markers of their developmental
lineage. Although these receptors have been well characterized in electrophysiological, …